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Ovarian hyperstimulation syndrome (OHSS) is 
a potential complication of ovarian stimulation in
the treatment of infertility. Severe forms of OHSS
appear in 0.5–5.0% of in vitro fertilization (IVF)
cycles.1 A critical condition develops with massive
ascites or pleural effusion, dyspnea, hemocon-
centration and oliguria that can be life-threatening.
The underlying cause is an increase in the capillary
permeability of the ovaries and mesothelial sur-
faces with extravasation of protein-rich fluid, which
in turn causes hypovolemia, reduced organ per-
fusion and the risk of thromboembolism. Several
angiogenic and vasoactive cytokines, including
vascular endothelial growth factor (VEGF), inter-
leukin (IL)-6, IL-8, tumor necrosis factor-α (TNF-α)
and angiotensin II, produced from multiple cor-
pora lutea were attributed to pathogenetic factors.2
A better understanding of the underlying patho-
physiologic and signal mechanisms would be
helpful for prevention and treatment.
Human Chorionic Gonadotropin is a
Contributing Inducing Factor of OHSS
The development of OHSS following ovarian stim-
ulation with gonadotropins is mainly associated
with the administration of human chorionic go-
nadotropin (hCG) as the syndrome rarely develops
if it is withheld.2 In addition, OHSS becomes
more severe after pregnancy occurs. VEGF has
been found to be an important mediator of OHSS.
Expressions of VEGF mRNA and secretion of VEGF
protein are positively regulated by hCG in granu-
losa lutein cells.3 VEGF stimulates new blood vessel
development and vascular hyperpermeability by
acting through VEGF receptor 2 (VEGFR-2) on
the endothelial cells. However, the signal pathway
of hCG-induced VEGF secretion is still unclear and
deserves further investigation.
Other Factors and Vasoactive Cytokines
May Contribute to OHSS
Lysophosphatidic acid (LPA) has been detected
to exist at considerable amounts in the follicular
fluid of preovulatory follicles. Recently, LPA has
been found to be an important regulator of IL-8
and IL-6 in granulosa lutein cells.3 LPA induces
IL-8 and IL-6 expression through LPA receptors,
mitogen-activated protein kinase and nuclear
factor-κB dependent pathways. LPA-induced IL-8
and IL-6 increase the permeability of the endothe-
lial monolayer. However, the signal pathways of
IL-8 and IL-6 in endothelial cells leading to vas-
cular hyperpermeability in OHSS remain elusive.
In addition to VEGF, the relative effects of IL-8,
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IL-6, TNF-α and angiotensin II that contribute to
OHSS are unclear and need further clarification.
Prevention of OHSS
Coasting with cessation of gonadotropin has been
widely adopted to reduce OHSS in high-risk con-
ditions with massive follicular growth.4 However,
prolonged coasting has the drawback of a reduced
pregnancy rate. Therefore, what constitutes an op-
timal strategy for coasting deserves further study.
Prophylactic albumin could be helpful in prevent-
ing OHSS in high-risk patients. However, it does
not completely eliminate severe OHSS.4 Luteal
support with progesterone and estradiol, rather
than hCG supplements, reduces the risk of OHSS.
Adoption of the strategy of blastocyst transfer may
permit more time in which the possibility of OHSS
can be evaluated. Elective cryopreservation of all
embryos for postponement of transfer can prevent
the occurrence of late OHSS from pregnancy. For
high-risk patients, mild ovarian stimulation with
the gonadotropin and gonadotropin-releasing
hormone (GnRH) antagonist protocol may 
prevent OHSS.
hCG is Currently Used as Standard
Method for Triggering Oocyte
Maturation, But It Increases OHSS Risk
hCG has been used as a substitute luteinizing
hormone (LH) surge because it has structural 
homology and results in similar action. Both LH
and hCG are heterodimeric glycoproteins with
identical α subunits and different β subunits. They
can induce ovulation and luteinization as well as
support luteal cells. The major difference between
the two hormones is the pharmacokinetics of
clearance. Compared with LH, hCG has a slower
plasma metabolic clearance. The calculated half-life
of hCG was 2.3 days and that of LH was 3–5
hours.5 hCG has sustained luteotropic action be-
cause of its prolonged circulating half-life that
may predispose to OHSS. Recently, Nargund et al
reported that reduction of hCG dosage to 2500 IU
for triggering oocyte maturation decreased the
incidence of OHSS in high-risk patients.6
Use of LH for the Replacement of hCG in
Triggering Oocyte Maturation
The development of recombinant LH (rLH) may
offer an opportunity to replace hCG. The European
rLH study group performed a prospective and com-
parative study on the effective dose of rLH required
to induce oocyte maturation and luteinization in
patients undergoing IVF.5 A dose of 15,000–30,000
IU rLH compared with 5000 IU hCG resulted in
a similar number of oocytes, embryos and preg-
nancies. The use of rLH achieved a significant 
reduction in OHSS compared with hCG. More
effort should be made to use rLH as an alternative
to hCG as the standard method for induction of
oocyte maturation and OHSS prevention.
Use of GnRH Agonist to Induce LH Surge
in Non-agonist or Antagonist Cycles
GnRH agonist can stimulate the release of LH and
follicle stimulating hormone. It has been used to
induce endogenous LH surge in ovulation induc-
tion. However, the pregnancy rate was lower than
that with the use of hCG. This disappointing result
has been attributed to a luteolytic effect caused by
the agonist. The introduction of GnRH antagonist
protocols has resulted in renewed interest in the
use of GnRH agonist to trigger ovulation. Recently,
a prospective randomized controlled study of
IVF patients found no differences in the number
of mature oocytes, fertilization rates, embryo 
development and implantation rates between
the GnRH agonist and hCG groups.7 The risk of
OHSS was significantly reduced in the former
group. The use of GnRH agonist to induce final
oocyte maturation in the antagonist protocol
with appropriate luteal support may be a good
alternative to avoid OHSS and deserves further
investigation.
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Dopamine Agonist (Cabergoline) Inhibits
VEGFR-2-mediated Vascular
Hyperpermeability
The downstream signals of VEGFR-2 in endothelial
cells for vascular permeability in OHSS may in-
volve VE-cadherin8 and merits further delineation.
It was recently found that dopamine or dopamine
receptor 2 (DR-2) agonists transact inhibition of
VEGFR-2 dependent vascular permeability and
angiogenesis through DR-2 of endothelial cells.9
Gomez et al first investigated the effect of DR-2
agonist (cabergoline) on OHSS in a rat model.10
They found that a low dose of cabergoline reversed
vascular permeability without affecting luteal an-
giogenesis. Alvarez et al conducted a pilot study
on patients at risk of developing OHSS who were
given cabergoline (0.5 mg/day) orally from the
day of hCG for 9 days.1 They observed that ascites,
hemoconcentration, vascular hyperpermeability
and OHSS were significantly reduced. They further
demonstrated that implantation and pregnancy
outcome were not affected by cabergoline treat-
ment.11 However, the case number in their series
was small. In addition, angiogenesis is a fun-
damental step in implantation and pregnancy.
The effects of cabergoline on OHSS, angiogenesis
of implantation and pregnancy outcome deserve
further study.
Conclusions
Fluid, electrolyte and albumin supplements or
paracentesis and thoracentesis have been used 
as primary treatments for severe OHSS. Recent 
advances in prevention and treatment have sig-
nificantly reduced the incidence of OHSS. Mild
stimulation of the ovaries may avert the develop-
ment of OHSS. The use of GnRH agonist to induce
final oocyte maturation in the antagonist protocol
may reduce OHSS. Coasting is effective in reducing
OHSS, but what constitutes optimal timing needs
further investigation. Reduction of hCG dosage
for triggering oocyte maturation may diminish
OHSS. The effects of cabergoline on the prevention
of OHSS merit further study. In-depth study of
signal pathways in luteal and implantation angio-
genesis as well as vascular permeability would be
helpful for appropriate targeting therapy of OHSS.
The possible role of VEGF inhibitor or immuno-
modulators of TNF-α in the treatment of OHSS
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Prevention
Mechanisms
Management
Strategies before oocyte retrieval
• Mild stimulation
• Coasting
• Reduction of hCG dose
• GnRH agonist for triggering ovulation
• rLH for triggering ovulation
• Cancellation of cycle
Strategies after oocyte retrieval
• Albumin, fluid and electrolyte supplement
• Luteal support with progesterone and estradiol,
 instead of hCG supplements
• Dopamine agonist (cabergoline)
• Blastocyst transfer and sonography for ovaries and ascites
• Cryopreservation of all embryos
Multiple corpora
luteae in ovary
Endothelial cells Hyperpermeability with
fluid extravasation
Secretion of VEGF, IL-8,
IL-6, TNF-α, angiotensin II,
etc.
Figure.Mechanisms and management of ovarian hyperstimulation syndrome.
may deserve further investigation. The use of rLH
for inducing oocyte maturation is imperative in the
prevention of OHSS in the future. The mechanisms
and management of OHSS are summarized in the
Figure.
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